BROXIVAN 3 mg/ml ORAL SOLUTION
How to use BROXIVAN 3 mg/ml ORAL SOLUTION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Broxivan 3 mg/ml Oral Solution EFG
ambroxol hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Broxivan and what is it used for
- What you need to know before you take Broxivan
- How to take Broxivan
- Possible side effects
- Storage of Broxivan
- Contents of the pack and other information
1. What is Broxivan and what is it used for
Ambroxol, the active substance of this medicine, belongs to a group of medicines called mucolytics, which act by decreasing the viscosity of mucus, making it more fluid and easier to eliminate.
This medicine is indicated for the treatment of dissolution of mucus in diseases of the bronchi and lungs with thick mucus, in adults and children from 2 years of age.
You should consult a doctor if it gets worse or if it does not improve after 5 days (within 3 days in children under 6 years of age).
2. What you need to know before you take Broxivan
Do not take Broxivan
- If you are allergic to ambroxol hydrochloride or any of the other ingredients of this medicine (listed in section 6).
- In children under 2 years of age.
Warnings and precautions
Consult your doctor or pharmacist before taking this medicine.
- If you have severe kidney or liver problems, this medicine should only be used after consulting a doctor.
- If you have a disorder of bronchial motor activity (lung problems) along with a large production of secretions (risk of a mucous plug), you should not take this medicine;
- If you experience a skin rash (including lesions of the mucous membranes such as mouth, throat, nose, eyes, genitals), stop using this medicine and consult your doctor immediately. There have been reports of severe skin reactions associated with the administration of ambroxol.
- If you have a histamine intolerance (allergy to histamine-rich foods). In that case, you should avoid long-term treatment, as the active substance of this medicine influences histamine metabolism and may cause intolerance symptoms (such as headache, nasal discharge, itching).
- If you are prone to developing peptic ulcers, as mucolytics (such as this medicine) may alter the gastric mucosa barrier. In this case, you should not take this medicine.
Children
Do not give this medicine to children under 2 years of age.
In children from 2 to 4 years of age with persistent or recurrent cough, you should consult a doctor before treatment.
Other medicines and Broxivan
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
No interactions of ambroxol with other medicines are known.
While taking ambroxol, you should not use any medicine that suppresses the cough reflex (so-called antitussives). The cough reflex is important for coughing up the liquefied mucus and thus eliminating it from the lungs.
Taking Broxivan with food and drinks
This medicine can be taken with or without food.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is no evidence of adverse effects during pregnancy. However, you should not take ambroxol during the first three months of pregnancy.
Ambroxol hydrochloride is excreted in breast milk, so this medicine is not recommended during breastfeeding.
Animal studies do not indicate direct or indirect harmful effects with respect to fertility.
Driving and using machines
No studies on the effects of ambroxol on the ability to drive and use machines have been performed. However, there is no evidence of any effect of this medicine on the ability to drive and use machines.
Broxivan contains benzoic acid
This medicine contains 0.51 mg of benzoic acid in each ml.
Broxivan contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per ml, i.e. it is essentially "sodium-free".
3. How to take Broxivan
Follow exactly the administration instructions of this medicine given by your doctor. In case of doubt, consult your doctor or pharmacist again.
Do not take this medicine for more than 5 days (within 3 days in children under 6 years of age) without consulting your doctor.
Recommended dose
Use in adults
10 ml, 3 times a day (every 8 hours), which means a maximum daily dose of 90 mg of ambroxol hydrochloride.
Use in children and adolescents
Adolescents over 12 years of age
10 ml, 3 times a day (every 8 hours), which means a maximum daily dose of 90 mg of ambroxol hydrochloride.
Children from 6 to 12 years of age
5 ml, 2-3 times a day, (every 8-12 hours, as needed), which means a maximum daily dose of 45 mg of ambroxol hydrochloride. After 2-3 days, once the patient improves, the dosage regimen can be reduced to 2 times a day every 12 hours.
Children from 2 to 5 years of age
2.5 ml, 3 times a day (every 8 hours), which means a maximum daily dose of 22.5 mg of ambroxol hydrochloride. After 2-3 days, once the patient improves, the dosage regimen can be reduced to 2 times a day every 12 hours.
Broxivan can be taken with or without food.
To facilitate the administration of the oral solution, the package contains a volume measuring device.
You should consult a doctor if it gets worse or if it does not improve after 5 days (within 3 days in children under 6 years of age).
If you take more Broxivan than you should
No cases of ambroxol overdose are known.
If you accidentally take more medicine than recommended, ambroxol side effects may occur. The symptoms of overdose are consistent with the side effects of ambroxol when taken in the recommended doses and symptomatic treatment may be necessary.
In case of overdose or accidental ingestion, consult your doctor or pharmacist, or call the Toxicological Information Service, phone 915 620 420, indicating the medicine and the amount ingested.
If you forget to take Broxivan
Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may occur:
Common(may affect up to 1 in 10 people):
- alteration of taste,
- nausea,
- decreased sensitivity in the mouth and pharynx (the passages that lead to the stomach and lungs)
Uncommon(may affect up to 1 in 100 people):
- diarrhea,
- vomiting, dyspepsia,
- dry mouth,
- abdominal pain
Rare(may affect up to 1 in 1,000 people):
- allergic reactions,
- exanthema,
- urticaria,
- dry throat
Frequency not known(frequency cannot be estimated from the available data)
- anaphylactic reactions including anaphylactic shock (potentially life-threatening allergic reactions),
- angioedema (rapid swelling of the skin, tissues under the skin, mucosa or submucosa),
- pruritus (itching of the skin),
- severe skin reactions (including erythema multiforme, Stevens-Johnson syndrome / toxic epidermal necrolysis and acute generalized exanthematous pustulosis).
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Broxivan
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date is the last day of the month shown. After opening the bottle for the first time, the medicine remains stable for 6 months.
This medicine does not require any special storage conditions.
Do not freeze.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Contents of the pack and other information
Composition of Broxivan
- The active substance is ambroxol hydrochloride. Each ml of oral solution contains 3 mg of ambroxol hydrochloride.
- The other ingredients are: sucralose, benzoic acid, hydroxyethylcellulose 10900-20300 mPA.s, disodium edetate, cherry flavor powder, vanilla flavor powder, concentrated hydrochloric acid, sodium hydroxide, purified water.
Appearance of the product and pack contents
Colorless to slightly yellowish liquid, transparent, with a vanilla and cherry flavor.
Brown glass bottles type III of 100 ml, 125 ml or 150 ml fill volume, closed with child-resistant plastic caps, which are also tamper-evident. The bottles are packaged in a cardboard box together with a plastic measuring cup.
The capacity of the plastic measuring cups is 2.5 ml, 5 ml and 10 ml.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer:
Marketing authorisation holder:
Medochemie Iberia S.A.
Rua Jose Maria Nicolau, n.o 6, 7.oB,
São Domingos de Benfica,
1500 662 Lisboa,
Portugal
Manufacturer
Medochemie Limited
1-10 Constantinoupoleos street,
3011 Limassol,
Cyprus
You can request more information about this medicine from the local representative of the marketing authorisation holder:
Local representative:
Medochemie Iberia S.A., Spanish branch
Avenida de las Águilas, nº 2 B; 5th floor, office 6,
28044 Madrid
Spain
This medicine is authorised in the Member States of the European Economic Area under the following names:
Portugal | Broxivan |
Bulgaria | Broxivan |
Cyprus | Broxivan |
Lithuania | Broxivan |
Malta | Broxivan |
Romania | Broxivan |
Slovakia | Broxivan |
Spain | Broxivan |
Date of last revision of this leaflet: August 2021
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to BROXIVAN 3 mg/ml ORAL SOLUTIONDosage form: ORAL SOLUTION/SUSPENSION/PULMONARY INHALATION, 15 mg/2 mlActive substance: ambroxolManufacturer: Laboratorio Aldo Union S.L.Prescription requiredDosage form: ORAL SOLUTION/SUSPENSION, 15 mgActive substance: ambroxolManufacturer: Laboratorios Cinfa S.A.Prescription not requiredDosage form: ORAL SOLUTION/SUSPENSION, 6 mg/mlActive substance: ambroxolManufacturer: Laboratorios Cinfa S.A.Prescription not required
Online doctors for BROXIVAN 3 mg/ml ORAL SOLUTION
Discuss questions about BROXIVAN 3 mg/ml ORAL SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
